Caldwell Sutter Capital’s aTyr Pharma ATYR Stock Holding History

Caldwell Sutter Capital’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31	Hold	52	–	–	﹤0.01%	916
2026 Q1	$41	Hold	52	–	–	﹤0.01%	874
2025 Q4	$41	Hold	52	–	–	﹤0.01%	861
2025 Q3	$38	Hold	52	–	–	﹤0.01%	855
2025 Q2	$264	Hold	52	–	–	﹤0.01%	822
2025 Q1	$157	Hold	52	–	–	﹤0.01%	861
2024 Q4	$188	Hold	52	–	–	﹤0.01%	871
2024 Q3	$92	Hold	52	–	–	﹤0.01%	886
2024 Q2	$81	Hold	52	–	–	﹤0.01%	898
2024 Q1	$101	Hold	52	–	–	﹤0.01%	895
2023 Q4	$73	Hold	52	–	–	﹤0.01%	933
2023 Q3	$82	Hold	52	–	–	﹤0.01%	868
2023 Q2	$112	Buy	+52	New	+$114	﹤0.01%	846

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Caldwell Sutter Capital's ATYR Position: Q2 2026 in Review

Caldwell Sutter Capital held its aTyr Pharma (ATYR) position steady in Q2 2026 at 52 shares worth $31. The position accounts for ﹤0.01% of the portfolio, ranked #916.

Caldwell Sutter Capital first reported a position in ATYR in Q2 2023 and has held it in 13 quarters since. The position peaked at $264 in Q2 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

Caldwell Sutter Capital held 52 shares of aTyr Pharma worth $31 as of Q2 2026.
Caldwell Sutter Capital left its aTyr Pharma share count unchanged in Q2 2026.
aTyr Pharma made up ﹤0.01% of Caldwell Sutter Capital's portfolio in Q2 2026, its #916 holding.
Caldwell Sutter Capital first reported a position in aTyr Pharma in Q2 2023 and has held it in 13 quarters since.
Caldwell Sutter Capital's aTyr Pharma position peaked at $264 in Q2 2025.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Caldwell Sutter Capital's 13F filing for Q2 2026, filed 5 Aug 2026.